News and Comments

Illumina, Roche and Fairness

  Thursday, February 09, 2012

Illumina (ILMN) is occupying the center stage these days. Roche’s persistent attempts to acquire ILMN, has opened investors’ eyes on the importance of this firm’s technology in moving away from the road of stagnation to that of innovation. Innovation is the insurance that guarantees the survival and growth of the drug companies in the future that has already begun. Illumina’s technologies and marketed state-of-the-art sequencers and gene analyzers have been a major contributor to the flourishing of information about the origins of diseases at the molecular level.  This capability, which lured Roche, was overlooked by Wall Street investors who have recently caused a selloff in the stock for theorized reasons. The real value of Illumina resides in its indispensability as the cornerstone of future advancement in medical diagnosis and treatment. With all the new-targeted drugs on the market and in the firms’ pipelines, the current diagnostic and treatment statuses are still far from perfect. More...

Compugen (CGEN): Advancing the Drug Discovery Process

  Thursday, August 12, 2010

With the evolution of the genomic and proteomic technologies, we highly regard and appreciate the firms that have invested in these technology towards breakthrough discoveries that are used in a therapeutic progress towards healing chronic and deadly diseases. One of these firms has offered us more than hints about what it can accomplish through its thoroughly developed technologies. The firm in question is Compugen (CGEN), is still small as measured by its market cap, but we see it as a future giant based on its achievements. Using its LEADS Platform and other proprietary algorithms and technologies, Compugen was capable of predicting in silico the existence of novel members of the B7/CD28 family of co-stimulatory proteins, and discovering an extracellular region of the predicted (previously unknown) membrane protein in the B7/CD28 family.  More...

A New State-Of-The-Art Diagnostic Test

  Wednesday, July 14, 2010
The Biotechnology Revolution: A New State-Of-The-Art Diagnostic Test

Genomics are changing the way medicine is being practiced, bringing to the labs state-of-the-art diagnostic tests that do much more than ruling in, or out diseases. The new laboratory tests enable physicians to determine the most effective treatment options for their patients’ diseases, to monitor the disease progression and install the treatment at the right time.  This is no dream any longer, but reality. The latest news about achievements in this domain comes from Life Technologies (LIFE) and Asuragen, which announced yesterday they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test that  enables clinicians to monitor and treat patients afflicted with chronic myeloid leukemia (CML).

Asuragen's clinically validated and cGMP manufactured the BCR/ABL1 Quant™ Test, which is  distributed by Life Technologies (LIFE) and runs on its Applied Biosystems’ CE-marked 7500 Fast Dx Real-Time PCR Instrument™. The test for leukemia progression is a quantitative in vitro diagnostic test. It helps doctors determine the most effective treatment options for CML. The test monitors the BCR-ABL1 to ABL1 ratio by reverse transcription quantitative polymerase chain reaction (RT-qPCR) on whole blood or bone marrow of diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML) patients expressing b2a2, b3a2 or e1a2 fusion transcripts. The test is intended as an aid in the assessment of complete cytogenetic response (CCyR), major molecular response (MMR), minimal residual disease and relapse in CML patients. 

The BCR-ABL1 fusion gene arises from a specific chromosome translocation, known as the Philadelphia chromosome or t (9:22). The resulting BCR/ABL1 fusion transcripts are present in approximately 95% of CML. If present, the expression level of the fusion transcript or its ratio to a reference transcript may be used to monitor disease progress. Monitoring the level of BCR/ABL1 may be helpful for both prognosis and management of Gleevec®, Tasigna®, Sutent® and Sprycell® kinase therapies in patients with leukemia disease.

To read the press release and about the firms go to:    

Asuragen and Life Technologies have plans to pursue future regulatory clearance for a BCR/ABL1 Quant test in the United States. 

See Also: Illumina (ILMN), Sequenom (SQNM), Clinical Data (CLDA), Compugen (CGEN) More...

COMPUGEN (CGEN): On the Road To Breakthroughs

  Tuesday, May 11, 2010

We expect to see breakthrough discoveries and treatments being made by Compugen through its far-reaching discovery and validation engines. We discussed many previous discoveries in past Prohost Letters and today news enabled us to witness an important revelation. The membrane protein, CGEN-928, which had no recognized function or potential clinical utility, could now serve as a multiple myeloma drug target thanks to Compugen’s discovery engines.  More...

Recent Postings



TOKAI (TKAOI) IDERA (IDRA) Pluristem (PSTI) Sanofi-Aventis (SAN) Biocryst (BCRX) NANTKWEST (NK) Inovio (INO) Illumina (ILMN) ISIS (ISIS) NOVOCURE (NVCR) RenenxBio (RGNX) SUNESIS PHARMACEUTICALS (SNSS) Array Pharmaceuticals (ARRY) VANDA (VNDA) Rapamune Human Longevity (HLI) Revlimid (lenolidamide) Sangamo (SGMO) Mirati Therapeutics (MRTX) Global Cell Therapeutics (GBT) Micromet (MITI) Roche (ROCHE) Auspex (ASPX) MODERNA Elan (ELN) Tysabri Amgen (AMGN) Valeant Pharmaceuticals International (VRX) Anacor (ANAC) KITE (KITE) Incyte (INCY) Intermune (ITMN) Agenus (AGEN) CompuGen (CGEN) Galena (GALE) Theravance Bio Pharma (TBPH) Ziofpharm (ZIOP) Intrexon (XON) Dendreon (DNDN) JOUNCE THERAPEUTICS (JNCE) ACADIA (ACAD) Ocular Therapeutix (OCUL) Advaxis (ADXS) Sequenom (SQNM) Abbott Laboratories (ABT) Regeneron (REGN) Telaprevir Idenix (IDIX) Akebia Therapeutics (AKAB) C4 Therapeutics ZALTRAP™ GlycoMimetics (GLYN) Aimmune Therapeutics (AIMT) AGOS (ARGS) ARGOS (ARGS) Bristol-Myers Squibb (BMY) Sanofi (SNA) Prolor Biotech (PBTH) Merck (MRK) KERYX (KERX) JUNO (JUNO) Alder Biopharmaceuticals (ALDR) Gilead (GILD) Dynavax (DVAX) ADVENTRIX (ANX) Prosensa (RNA) Vertex (VRTX) CEMPRA (CEMP) Theravance (THRX) Vitae Pharmaceuticals (VTAE) NEUROCRINE (NBIX) Jazz Pharmaceuticals (JAZZ) Sanofi (SNY) ARCA (ABIO) SERES THERAPEUTICS (MCRB) Editas (EDIT) Ariad (ARIA) HALOZYME (HALO) LEXICON (LXRX) GlaxoSmithKline (GSK) Benlysta (belimumab) Sarepta (SRPT) AERIE PHARMACEUTICALS ImmunoGen (IMGN) Alnylam (ALNY) OSI (OSIP) GUARDIAN HEALTH Human Genome Sciences (HGSI) Epizyme (EPZM) Velcade (bortezomib) Ridaforolimus SYNTA (SNTA) OncoCyte (OCX) AstraZeneca (AZN) CRISPR Therapeutics (CRSP) PTC Therapeutics (PTCT) Adaptimmune (ADAP) Spike Therapeutics (ONCE) INNOVIVA (INVA) Ionis (IONS) NEKTAR (NKTR)) Bellicum (BLCM) Onyx (ONXX) ABBVIE (ABBV) Multiple Myeloma galapagos (GLPG) Seattle Genetics (SGEN) Xoma (XOMA) PORTOLA (PTLA) Trastuzumab-DM1 REGULUS (RGLS) Endometrial Cancer Biogen Idec (BIIB) Agenus (AGEN BIOMARIN (BMRN) Herceptin Anadys (ANDS) Genentech Exelixis (EXEL) Roche (RHHBY) Intercept (ICPT) Zerenex Cytokinetics (CYTK)